Current Edition

Are Regulatory Service Providers Over-estimating AI’s Potential Impact on Process Transformation?

Within the next three years, the pharma and biotech industries will be at a point of deploying AI and machine learning to transform the pace and productivity of routine regulatory processes, according to Deloitte. By 2022, automated writing of clinical study reports will be happening as standard, using natural language processing. Alan White CEO of Arriello questions whether there is a danger that the industry is being oversold on the promise of AI.